Cariprazine hydrochloride

AbbVie is looking for business development opportunities which can fuel growth "in the next decade," CEO Rob Michael said. On a day when AbbVie revealed booming sales of Skyrizi and Rinvoq and another positive adjustment to its 2025 guidance, the company also is reportedly angling to bolster its long-term prospects by way of an acquisition, according to a Bloomberg report.The Illinois pharma is discussing a potential $1 billion deal to buy out New York City psychedelic drug specialist Gilgamesh Pharmaceuticals. The companies are already partners after AbbVie paid $65 million up front and pledged $1.95 billion in potential milestones last year to help develop candidates for major depressive disorder.While AbbVie didn’t specifically address the rumored deal during a conference call on Thursday, CEO Rob Michael did discuss in general how the company is thinking about business development.“When you look at the diverse, high-growth platform we have today, that’s really going to give us the opportunity to drive top-tier performance—a clear line of sight to growth—for at least the next eight years,” Michael said. “It’s really about how we set up the company to grow beyond Skyrizi and Rinvoq.”Michael added that the company will not lose patent protection for any of its significant growth drivers for the rest of this decade, which gives AbbVie the flexibility to invest more in R&D and to continue to acquire external innovation.Evidence of this philosophy is backed up by AbbVie’s recent acquisitions, including a $2.1 billion purchase a month ago of Capstan Therapeutics, which is developing in vivo CAR-T therapies for autoimmune and other disorders. In October, AbbVie spent $1.4 billion to acquire Aliada Therapeutics and its novel Alzheimer’s disease candidate.Gaining Aliada, added to a potential acquisition of Gilgamesh, bolsters AbbVie’s already healthy neuroscience portfolio. That business increased its sales by 24% in the second quarter as each of the company’s top four products “exceeded expectations,” according to AbbVie’s chief commercial officer, Jeff Stewart.“We are fully investing in neuroscience. We look forward to maintaining our leadership position there,” Stewart said. “We’re gonna keep feeding that engine.” The engine includes mood stabilizer Vraylar, which was up 16% to $900 million in sales; therapeutic Botox, which was up 14% to $928 million; migraine treatments Ubrelvy, which jumped 47% to $338 million; plus Qulipta, which saw an increase of 77% to $267 million.As for its immunology juggernauts, AbbVie reported sales of Skyrizi at $4.4 billion, which was a 62% increase year over year, while Rinvoq topped the $2 billion mark in quarterly sales for the first time, for a 42% increase.AbbVie jacked up its 2025 revenue guidance to $60.5 billion, which is an increase of $800 million from the company’s estimate three months ago. The company has increased its Skyrizi revenue projection by $600 million to $17.1 billion for the year, while decreasing its estimate for fading powerhouse Humira by $500 million to $3 billion for the year, “reflecting biosimilar competition,” CFO Scott Reents said. AbbVie did not adjust its 2027 projection of $31 billion for combined Skyrizi and Rinvoq sales, even though the products are tracking to exceed the figure. “We will update that at the appropriate time, but momentum is clearly there,” Michael said, adding that the company typically adjusts long-term guidance at the end of the year, often unveiling adjustments at the J.P. Morgan conference in January.As for its neuroscience portfolio, AbbVie has added $300 million, putting its projection for the year at $10.5 billion, which includes a $100 million increase for Parkinson’s disease drug Vyalev, which was approved in October of last year and generated $98 million in the second quarter, “reflecting strong international uptake,” Reents said.

据彭博社7月31日报道，全球生物制药巨头艾伯维（AbbVie）正在与专注于精神健康治疗的私营公司Gilgamesh Pharmaceuticals进行收购谈判，交易估值约为10亿美元。艾伯维与Gilgamesh的合作由来已久。2024年5月，艾伯维和Gilgamesh共同宣布合作开发下一代精神疾病治疗药物组合。根据合作协议条款，Gilgamesh将从艾伯维获得6500万美元的预付款，并有资格获得总计19.5亿美元的期权费和里程碑费用，以及从净销售额中位数到低两位数的分层版税。Gilgamesh的技术与产品Gilgamesh是一家专注于开发新型神经可塑原（neuroplastogens）的生物技术公司，旨在通过创新疗法治疗抑郁症、焦虑症和药物成瘾等精神疾病。该公司目前有两款核心管线处于二期临床试验阶段的候选药物：- GM-2505：一种短效5-HT2A受体激动剂，用于治疗重度抑郁症，其作用时间仅为60-90分钟。- GM-1020：一种口服NMDA受体拮抗剂，同样用于治疗重度抑郁症。今年5月，GM-2505在中期临床试验中取得了积极的初步结果，显示出良好的疗效和安全性。近年来，精神健康问题日益受到关注，全球有超过3亿人受到抑郁症的影响。根据Bloomberg Intelligence的分析，预计到2032年，精神健康领域的市场销售额将达到约45亿美元。此次收购不仅将增强艾伯维在精神疾病治疗方面的产品管线，还将使其在快速增长的市场中占据更有利的位置。结束语：此外，艾伯维目前销售的Vraylar药物已用于治疗精神分裂症和双相情感障碍，此次收购将进一步丰富其在精神健康领域的治疗方案。然而，收购谈判仍在进行中，仍有可能被推迟或最终破裂。如果收购成功，这将是艾伯维在精神健康领域的重要战略布局，进一步巩固其在该领域的市场地位。识别微信二维码，可添加药时空小编请注明：姓名+研究方向！